{"id":40092,"date":"2025-08-26T14:36:50","date_gmt":"2025-08-26T06:36:50","guid":{"rendered":"https:\/\/flcube.com\/?p=40092"},"modified":"2025-08-26T14:36:51","modified_gmt":"2025-08-26T06:36:51","slug":"walvax-biotechnology-reports-19-5-revenue-drop-faces-hpv-vaccine-impairment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40092","title":{"rendered":"Walvax Biotechnology Reports 19.5% Revenue Drop, Faces HPV Vaccine Impairment"},"content":{"rendered":"\n<p>China\u2011based Walvax Biotechnology Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/300142:SHE\">SHE: 300142<\/a>) disclosed its financial results for the first half of 2025, showing a <strong>19.47\u202f% year\u2011on\u2011year decline in operating revenue<\/strong> to <strong>\u00a51.154\u202fbillion<\/strong>. The dip was driven largely by a reduction in sales of its vaccine portfolio compared with the same period last year.<\/p>\n\n\n\n<p><strong>Revenue Breakdown<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Segment<\/th><th>H1\u202f2025 Revenue (\u00a5\u202fbn)<\/th><th>YoY Change<\/th><\/tr><\/thead><tbody><tr><td>Total Operating<\/td><td>1.154<\/td><td><strong>\u201119.47\u202f%<\/strong><\/td><\/tr><tr><td>Non\u2011EPI Vaccines<\/td><td>1.052<\/td><td><strong>\u201119.61\u202f%<\/strong><\/td><\/tr><tr><td>Overseas Business<\/td><td>0.214<\/td><td>\u2191 (details below)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><em>The decline in non\u2011EPI vaccine sales reflects broader market pressure and a shift in the HPV vaccine landscape.<\/em><\/p>\n\n\n\n<p><strong>HPV Vaccine Impairment<\/strong><br>Walvax recorded an impairment loss related to its HPV vaccine line:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Intangible assets &amp; R&amp;D book value<\/strong>: \u00a5748.2951\u202fmillion<\/li>\n\n\n\n<li><strong>Recoverable amount<\/strong>: \u00a5672\u202fmillion<\/li>\n\n\n\n<li><strong>Impairment provision<\/strong>: \u00a576.2951\u202fmillion<\/li>\n<\/ul>\n\n\n\n<p>The impairment stems from changing demand dynamics and competitive pressures in the HPV market, prompting a reassessment of the asset\u2019s recoverable value.<\/p>\n\n\n\n<p><strong>Export Performance Amid China\u2019s Pharma Trade Shift<\/strong><\/p>\n\n\n\n<p>According to the China Chamber of Commerce for Import &amp; Export of Medicines &amp; Health Products, China\u2019s pharmaceutical exports grew <strong>3.8\u202f% YoY<\/strong> to <strong>$54.539\u202fbillion<\/strong> in H1\u202f2025, while imports fell <strong>3.92\u202f%<\/strong> to <strong>$20.456\u202fbillion<\/strong>. This trend reflects an import\u2011substitution effect driven by domestic industrial upgrades.<\/p>\n\n\n\n<p><strong>Walvax\u2019s Global Footprint<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Overseas revenue<\/strong>: \u00a5214\u202fmillion (\u2248$29\u202fmillion)<\/li>\n\n\n\n<li><strong>New export markets<\/strong>: Ghana and Myanmar<\/li>\n\n\n\n<li><strong>Total countries served<\/strong>: 24<\/li>\n\n\n\n<li><strong>Cumulative export volume<\/strong>: >63\u202fmillion doses<\/li>\n<\/ul>\n\n\n\n<p>Walvax remains among the top domestic vaccine exporters (excluding COVID\u201119 vaccines) for several consecutive years, underscoring its commitment to high\u2011quality international business development.<\/p>\n\n\n\n<p><strong>Outlook and Strategic Focus<\/strong><br>Walvax\u2019s management highlighted the following priorities for the remainder of 2025:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>R&amp;D acceleration<\/strong> \u2013 Further investment in next\u2011generation vaccine candidates and platform technologies.<\/li>\n\n\n\n<li><strong>Market diversification<\/strong> \u2013 Expand presence in emerging markets, leveraging existing export channels.<\/li>\n\n\n\n<li><strong>Cost discipline<\/strong> \u2013 Optimize manufacturing efficiencies to offset revenue volatility.<\/li>\n<\/ol>\n\n\n\n<p>Despite the current revenue decline, Walvax\u2019s robust export performance and strategic emphasis on innovation position it to navigate the evolving global pharmaceutical landscape.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/\u6c83\u68ee\u751f\u7269\uff1a2025\u5e74\u534a\u5e74\u5ea6\u62a5\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u6c83\u68ee\u751f\u7269\uff1a2025\u5e74\u534a\u5e74\u5ea6\u62a5\u544a.\"><\/object><a id=\"wp-block-file--media-5802d93d-6ade-49f6-9989-9ba1d69f7715\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/\u6c83\u68ee\u751f\u7269\uff1a2025\u5e74\u534a\u5e74\u5ea6\u62a5\u544a.pdf\">\u6c83\u68ee\u751f\u7269\uff1a2025\u5e74\u534a\u5e74\u5ea6\u62a5\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/\u6c83\u68ee\u751f\u7269\uff1a2025\u5e74\u534a\u5e74\u5ea6\u62a5\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-5802d93d-6ade-49f6-9989-9ba1d69f7715\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China\u2011based Walvax Biotechnology Co., Ltd. (SHE: 300142) disclosed its financial results for the first half&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40095,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,1152,332],"class_list":["post-40092","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-she-300142","tag-walvax-biotechnology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Walvax Biotechnology Reports 19.5% Revenue Drop, Faces HPV Vaccine Impairment - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2011based Walvax Biotechnology Co., Ltd. (SHE: 300142) disclosed its financial results for the first half of 2025, showing a 19.47\u202f% year\u2011on\u2011year decline in operating revenue to \u00a51.154\u202fbillion. The dip was driven largely by a reduction in sales of its vaccine portfolio compared with the same period last year.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40092\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Walvax Biotechnology Reports 19.5% Revenue Drop, Faces HPV Vaccine Impairment\" \/>\n<meta property=\"og:description\" content=\"China\u2011based Walvax Biotechnology Co., Ltd. (SHE: 300142) disclosed its financial results for the first half of 2025, showing a 19.47\u202f% year\u2011on\u2011year decline in operating revenue to \u00a51.154\u202fbillion. The dip was driven largely by a reduction in sales of its vaccine portfolio compared with the same period last year.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40092\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-26T06:36:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-26T06:36:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2610.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40092#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40092\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Walvax Biotechnology Reports 19.5% Revenue Drop, Faces HPV Vaccine Impairment\",\"datePublished\":\"2025-08-26T06:36:50+00:00\",\"dateModified\":\"2025-08-26T06:36:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40092\"},\"wordCount\":320,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40092#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2610.webp\",\"keywords\":[\"Finanical Reports\",\"SHE: 300142\",\"Walvax Biotechnology\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40092#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40092\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40092\",\"name\":\"Walvax Biotechnology Reports 19.5% Revenue Drop, Faces HPV Vaccine Impairment - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40092#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40092#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2610.webp\",\"datePublished\":\"2025-08-26T06:36:50+00:00\",\"dateModified\":\"2025-08-26T06:36:51+00:00\",\"description\":\"China\u2011based Walvax Biotechnology Co., Ltd. (SHE: 300142) disclosed its financial results for the first half of 2025, showing a 19.47\u202f% year\u2011on\u2011year decline in operating revenue to \u00a51.154\u202fbillion. The dip was driven largely by a reduction in sales of its vaccine portfolio compared with the same period last year.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40092#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40092\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40092#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2610.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2610.webp\",\"width\":1080,\"height\":608,\"caption\":\"Walvax Biotechnology Reports 19.5% Revenue Drop, Faces HPV Vaccine Impairment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40092#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Walvax Biotechnology Reports 19.5% Revenue Drop, Faces HPV Vaccine Impairment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Walvax Biotechnology Reports 19.5% Revenue Drop, Faces HPV Vaccine Impairment - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2011based Walvax Biotechnology Co., Ltd. (SHE: 300142) disclosed its financial results for the first half of 2025, showing a 19.47\u202f% year\u2011on\u2011year decline in operating revenue to \u00a51.154\u202fbillion. The dip was driven largely by a reduction in sales of its vaccine portfolio compared with the same period last year.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40092","og_locale":"en_US","og_type":"article","og_title":"Walvax Biotechnology Reports 19.5% Revenue Drop, Faces HPV Vaccine Impairment","og_description":"China\u2011based Walvax Biotechnology Co., Ltd. (SHE: 300142) disclosed its financial results for the first half of 2025, showing a 19.47\u202f% year\u2011on\u2011year decline in operating revenue to \u00a51.154\u202fbillion. The dip was driven largely by a reduction in sales of its vaccine portfolio compared with the same period last year.","og_url":"https:\/\/flcube.com\/?p=40092","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-26T06:36:50+00:00","article_modified_time":"2025-08-26T06:36:51+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2610.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40092#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40092"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Walvax Biotechnology Reports 19.5% Revenue Drop, Faces HPV Vaccine Impairment","datePublished":"2025-08-26T06:36:50+00:00","dateModified":"2025-08-26T06:36:51+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40092"},"wordCount":320,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40092#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2610.webp","keywords":["Finanical Reports","SHE: 300142","Walvax Biotechnology"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40092#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40092","url":"https:\/\/flcube.com\/?p=40092","name":"Walvax Biotechnology Reports 19.5% Revenue Drop, Faces HPV Vaccine Impairment - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40092#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40092#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2610.webp","datePublished":"2025-08-26T06:36:50+00:00","dateModified":"2025-08-26T06:36:51+00:00","description":"China\u2011based Walvax Biotechnology Co., Ltd. (SHE: 300142) disclosed its financial results for the first half of 2025, showing a 19.47\u202f% year\u2011on\u2011year decline in operating revenue to \u00a51.154\u202fbillion. The dip was driven largely by a reduction in sales of its vaccine portfolio compared with the same period last year.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40092#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40092"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40092#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2610.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2610.webp","width":1080,"height":608,"caption":"Walvax Biotechnology Reports 19.5% Revenue Drop, Faces HPV Vaccine Impairment"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40092#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Walvax Biotechnology Reports 19.5% Revenue Drop, Faces HPV Vaccine Impairment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2610.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40092","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40092"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40092\/revisions"}],"predecessor-version":[{"id":40096,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40092\/revisions\/40096"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40095"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40092"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40092"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40092"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}